Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Debt (2020 - 2026)

Myriad Genetics has reported Non-Current Debt over the past 4 years, most recently at $119.9 million for Q4 2025.

  • Quarterly Non-Current Debt rose 202.78% to $119.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $119.9 million through Dec 2025, up 202.78% year-over-year, with the annual reading at $119.9 million for FY2025, 202.78% up from the prior year.
  • Non-Current Debt was $119.9 million for Q4 2025 at Myriad Genetics, roughly flat from $119.5 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $119.9 million in Q4 2025 and troughed at $38.4 million in Q2 2023.
  • The 3-year median for Non-Current Debt is $38.9 million (2024), against an average of $57.0 million.
  • Year-over-year, Non-Current Debt rose 1.04% in 2024 and then skyrocketed 206.41% in 2025.
  • A 3-year view of Non-Current Debt shows it stood at $38.5 million in 2023, then rose by 2.86% to $39.6 million in 2024, then skyrocketed by 202.78% to $119.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Non-Current Debt are $119.9 million (Q4 2025), $119.5 million (Q3 2025), and $59.3 million (Q1 2025).